CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
NET REVENUE
Clinical Services	$ 59,540	$ 55,547	$ 116,511	$ 108,455
Pharma Services	8,206	6,717	14,658	11,238
Total Revenue	67,746	62,264	131,169	119,693
COST OF REVENUE	37,216	34,912	73,336	69,392
GROSS PROFIT	30,530	27,352	57,833	50,301
Operating expenses:
General and administrative	20,983	18,432	38,050	35,450
Research and development	1,073	947	2,029	1,809
Sales and marketing	7,680	6,132	14,455	11,779
Total operating expenses	29,736	25,511	54,534	49,038
Income from Operations	794	1,841	3,299	1,263
Interest expense, net	1,407	1,411	2,892	2,775
Other expense	124	0	62	0
Income (loss) before taxes	(737)	430	345	(1,512)
Income tax expense (benefit)	(357)	(53)	81	(832)
NET INCOME (LOSS)	(380)	483	264	(680)
Deemed dividends on preferred stock	947	929	1,950	1,822
Amortization of preferred stock beneficial conversion feature	1,824	1,710	3,677	3,383
Gain on redemption of preferred stock	(9,075)	0	(9,075)	0
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ 5,924	$ (2,156)	$ 3,712	$ (5,885)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic (in dollars per share)	$ 0.07	$ (0.03)	$ 0.05	$ (0.07)
Diluted (in dollars per share)	$ 0.07	$ (0.03)	$ 0.04	$ (0.07)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic (in shares)	81,017	79,413	80,789	79,075
Diluted (in shares)	90,168	79,413	89,305	79,075